Omthera Fish-Oil Drug Hooks AstraZeneca in $323M Buyout

Share:

AstraZeneca plc’s planned buyout of Omthera Pharmaceuticals Inc. to gain Phase III-validated Epanova, the anti-triglyceride therapy based on ultra-pure fish oil, puts the firm at a “distinct commercial advantage” over Amarin Corp. plc, with its recently launched Vascepa (icosapent ethyl), said Decision Resources (DR) analyst Paramjit Narang.

http://www.bioworld.com/content/omthera-fish-oil-drug-hooks-astrazeneca-323m-buyout-0

Tweet